ClinicalTrials.gg
CompletedNCT03045809WISHUpdated Sep 11, 2019Results posted

Women's Improvement of Sexual Health (WISH) Demonstration Project

An observational study in Sexually Transmitted Disease, Bacterial Vaginosis and Vaginal Candidiasis, sponsored by Janneke van de Wijgert. Completed at 1 site in Rwanda. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-11.

Sponsored by Janneke van de Wijgert · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
705
Ages
18 Years and older
Sex
Female
01

Study summary

The current standard of care for urogenital infections in Rwanda is syndromic management. Many urogenital infections are asymptomatic and therefore completely missed, and the management of vaginal discharge syndrome is known to be suboptimal. The primary objective of this study is to evaluate whether it is feasible to improve urogenital infection care in high risk women in Kigali, Rwanda, using point of care (POC) diagnostic testing for HIV, Trichomonas vaginalis (TV), and bacterial vaginosis (BV) in all women; POC testing for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and syphilis in pregnant women and women assessed to be at high risk for these infections using a risk scoring questionnaire; and management of vaginal candidiasis, urinary tract infection (UTI), genital ulcers/inguinal bubos, and lower abdominal pain in women reporting relevant symptoms. The secondary objectives of this study are 1) to evaluate the performance and 2) to obtain the opinions of Rwandan stakeholders.

Read the detailed description

This is a cross-sectional study. The improved urogenital infection care services will be advertised to women in Kigali, Rwanda, targeting women with urogenital complaints as well as women without urogenital complaints who have had high risk behavior. The services will be available for free at the research clinic for the duration of the project. All consenting women who attend the research clinic during the study period will be offered:

  1. Voluntary counselling and testing for HIV.
  2. Urine pregnancy test if indicated and contraception counselling.
  3. POC testing for UTI if UTI symptoms are present.
  4. POC testing for TV and BV regardless of symptoms, and management of vaginal candidiasis based on symptom-reporting.
  5. POC testing for syphilis and CT/NG if pregnant or considered at risk by risk scoring questionnaire.
  6. Syndromic management of genital ulcers/inguinal bubos and lower abdominal pain.
  7. Treatment and partner notification and treatment as appropriate, and referrals to antenatal, family planning, HIV and cervical cancer screening care.

Information about sociodemographics, risk behavior, sexual and reproductive health history and current urogenital symptoms will be collected during the clinic visit. Women can opt out of each service offered. Services will be delivered within one half day. However, women can choose to leave before all results are available, and be contacted by study staff when results are available, which is particularly relevant for women undergoing CT/NG POC testing (which takes about 90 minutes).

Vaginal swabs for storage will be taken from all consenting women (women can choose between self- or clinician-sampling) for additional research testing at the end of the study to allow for performance evaluation of the CT/NG, TV and BV POC tests.

Opinions of stakeholders will be gathered during workshops (one before and one after completion of the study) and in-depth interviews (IDIs).

02

Conditions studied

  • Sexually Transmitted Disease
  • Bacterial Vaginosis
  • Vaginal Candidiasis
  • Urinary Tract Infections

Keywords

  • Syndromic management
  • Point of care testing
03

In context

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

This study's enrollment of 705 is above the median of 578 across 93 observational studies indexed under Sexually Transmitted Diseases.

Browse Sexually Transmitted Diseases studies →

Lead sponsor

Janneke van de Wijgert is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant will not be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, at least 18 years old (no upper age limit)
  • At high risk of /STIs, defined as having had more than one sexual partner in the last 12 months OR having been treated for an STI in the last 12 months
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Already participated in this study before (each woman can only participate once)
  • Participating in another health intervention study
  • For any other reason as judged by the Principal Investigator (these reasons will be recorded)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
705 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Women at risk of urogenital infections

    Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.

    Diagnostic Test: Urogenital infection point-of-care tests

Interventions

  • Diagnostic testUrogenital infection point-of-care tests

    Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).

06

What researchers measure

Primary outcomes

  1. Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators)

    Clinical monitoring and evaluation indicators: numbers of women with positive CT/NG or syphilis risk scores, number of pelvic exams done, etc (see row titles in the table)

    Time frame: Each participant was assessed at one main study visit, which lasted up to 4 hours.

  2. Feasibility of Integrating Point-of-care Testing (Client Satisfaction Surveys)

    Answers to questions about experiences with the procedures (client satisfaction survey).

    Time frame: Each client satisfaction survey was conducted at a main visit and lasted up to 30 min.

  3. Performance of Syndromic Management With or Without Integration of Point-of-care Tests

    With performance we mean sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). We determined the number of women who would have received treatment for BV, VVC, TV, NG, and/or CT in the following situations: 1) if we would have followed the WHO syndromic management algorithms for vaginal discharge and lower abdominal pain; and 2) based on the POCT-based WISH algorithms (this is what we did in real life during the study), and compared each of these with gold standard infection-specific diagnoses. The results of the first comparison are reported in the first column and results of the second comparison in the second column.

    Time frame: Each participant was assessed at one main study visit, which lasted up to 4 hours.

07

Results

Posted Sep 11, 2019
Limitations and caveats
The study was implemented in a high prevalence population by experienced staff. Additional studies are required in low prevalence settings and in public primary care clinics. Our recruitment strategies mostly attracted women with symptoms.

Participant flow

At risk women regardless of symptoms were enrolled between 7-2016 and 3-2017. Recruitment activities were implemented by study staff with the help of community mobilizers. They organized recruitment meetings, and distributed flyers. Women were encouraged to refer their friends.

Participant flow — Overall Study
MilestoneWomen at Risk of Urogenital Infections.
Started705
Attended an additional visit (if needed)51
Completed705
Not completed0

Outcome measures

PrimaryFeasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators)

Clinical monitoring and evaluation indicators: numbers of women with positive CT/NG or syphilis risk scores, number of pelvic exams done, etc (see row titles in the table)

Time frame:
Each participant was assessed at one main study visit, which lasted up to 4 hours.
Reported as:
Count of participants · Participants
Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators)
ParticipantsWomen at Risk of Urogenital Infections.
Had a positive CT/NG risk score396
Had a positive syphilis risk score378
Underwent a pelvic examination399
Had any abnormality during the pelvic examination216
Had at least one positive POCT result541
Received all positive POCT results at main visit505
Received inadequate treatment0
Needed and received a referral79
Had at least one partner requiring notification201
Required at least one additional visit51
PrimaryFeasibility of Integrating Point-of-care Testing (Client Satisfaction Surveys)

Answers to questions about experiences with the procedures (client satisfaction survey).

Time frame:
Each client satisfaction survey was conducted at a main visit and lasted up to 30 min.
Reported as:
Count of participants · Participants
Feasibility of Integrating Point-of-care Testing (Client Satisfaction Surveys)
ParticipantsWomen at Risk of Urogenital Infections.
Felt welcome at study clinic107
Thought medical services were of good quality107
Thought counselling was of good quality107
Thought visit duration was too long but worth it41
Thought visit duration was too long and not worth0
Willing to be tested in future even if asymptomati100
Willing to pay for services in future95
PrimaryPerformance of Syndromic Management With or Without Integration of Point-of-care Tests

With performance we mean sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). We determined the number of women who would have received treatment for BV, VVC, TV, NG, and/or CT in the following situations: 1) if we would have followed the WHO syndromic management algorithms for vaginal discharge and lower abdominal pain; and 2) based on the POCT-based WISH algorithms (this is what we did in real life during the study), and compared each of these with gold standard infection-specific diagnoses. The results of the first comparison are reported in the first column and results of the second comparison in the second column.

Time frame:
Each participant was assessed at one main study visit, which lasted up to 4 hours.
Reported as:
Number · % (sensitivity/specificity/PPV/NPV)
Performance of Syndromic Management With or Without Integration of Point-of-care Tests
% (sensitivity/specificity/PPV/NPV)WHO Syndromic Management (Entire Study Population)WISH (Entire Study Population)
Chlamydia sensitivity58.3 (45.5 to 70.2)71.7 (58.3 to 81.7)
Chlamydia specificity44.7 (40.8 to 48.5)100 (100 to 100)
Chlamydia PPV8.9 (6.5 to 12.1)100 (100 to 100)
Chlamydia NPV92 (88.4 to 94.6)97.4 (95.9 to 98.4)
Gonorrhea sensitivity66.0 (51.8 to 77.8)76.0 (62.2 to 85.9)
Gonorrhea specificity45.2 (41.4 to 49.0)100 (100 to 100)
Gonorrhea PPV8.4 (6.0 to 11.6)100 (100 to 100)
Gonorrhea NPV94.6 (91.4 to 96.6)98.2 (96.9 to 99.0)
Trichomonas vaginalis sensitivity60.4 (50.9 to 69.1)68.5 (59.2 to 76.5)
Trichomonas vaginalis specificity45.6 (41.6 to 49.7)97.4 (95.7 to 98.4)
Trichomonas vaginalis PPV17.5 (14.0 to 21.7)83.5 (74.4 to 89.8)
Trichomonas vaginalis NPV85.7 (81.3 to 89.2)94.2 (92.0 to 95.8)
Bacterial vaginosis sensitivity61.6 (52.7 to 69.7)95.2 (89.7 to 97.8)
Bacterial vaginosis specificity46.0 (41.9 to 50.2)41.2 (37.2 to 45.4)
Bacterial vaginosis PPV20.2 (16.4 to 24.5)26.4 (22.5 to 30.7)
Bacterial vaginosis NPV84.4 (79.9 to 88.1)97.5 (94.5 to 98.9)
Vulvovaginal candidiasis sensitivity74.6 (61.9 to 84.1)64.4 (51.4 to 75.6)
Vulvovaginal candidiasis specificity50.6 (46.6 to 54.5)69.4 (65.7 to 72.9)
Vulvovaginal candidiasis PPV12.4 (9.3 to 16.2)16.5 (12.2 to 21.8)
Vulvovaginal candidiasis NPV95.5 (92.7 to 97.3)95.4 (93.1 to 97.0)

Adverse events

Collected over Each participant was assessed at one main study visit, which lasted up to 4 hours.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Women at Risk of Urogenital Infections.0/705 (0%)0/705 (0%)2/705 (0.3%)
Most frequent other events
Most frequent other events
EventWomen at Risk of Urogenital Infections.
Allergic reaction to metronidazoleSkin and subcutaneous tissue disorders2/705

Baseline characteristics

All 705 women who attended a main visit. Women were aged 18 or older, and at risk of sexually transmitted infections (more than one sex partner and/or having been treated for at least one STI in the past year), with or without urogenital symptoms. HIV-positive and pregnant women were not excluded.

Age, Categorical
Age, Categorical(Participants)Women at Risk of Urogenital Infections.
<=18 years0
Between 18 and 65 years705
>=65 years0
Age, Continuous
Age, Continuous(years)Women at Risk of Urogenital Infections.
Mean32.9 (18 to 62)
Sex: Female, Male
Sex: Female, Male(Participants)Women at Risk of Urogenital Infections.
Female705
Male0
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Women at Risk of Urogenital Infections.
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Women at Risk of Urogenital Infections.
African (Rwandan)705
Region of Enrollment
Region of Enrollment(participants)Women at Risk of Urogenital Infections.
Rwanda705
Chlamydia trachomatis positive by gold standard test
Chlamydia trachomatis positive by gold standard test(Participants)Women at Risk of Urogenital Infections.
Count of participants60
Neisseria gonorrhoeae positive by gold standard test
Neisseria gonorrhoeae positive by gold standard test(Participants)Women at Risk of Urogenital Infections.
Count of participants50

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Rinda Ubuzima
    Kigali, Rwanda
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — The University of Liverpool and project investigators support open access but university-wide systems are not yet accessible and open access has not yet been negotiated with the Rwandan authorities.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Mar 2017, 8 months.

Results were first posted in Sep 2019, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2017
First posted
Feb 8, 2017
StartActual
Jul 5, 2016
Primary completionActual
Mar 14, 2017
CompletionActual
Aug 6, 2018
Results first posted
Sep 11, 2019
Last update
Sep 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03045809
Lead sponsor
Janneke van de Wijgert
Collaborators
Rinda Ubuzima, Rwanda, Institute of Tropical Medicine, Belgium
Responsible party
Janneke van de Wijgert (Professor, University of Liverpool) — Sponsor-investigator
First posted
Feb 8, 2017
Start date
Jul 5, 2016
Primary completion
Mar 14, 2017
Completion
Aug 6, 2018
Results posted
Sep 11, 2019
Last update
Sep 11, 2019

Study contacts

Janneke van de Wijgert, MD PhD MPH
principal investigator · University of Liverpool

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion